Vera Therapeutics (VERA) Operating Expenses (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Operating Expenses data on file, last reported at $125.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 118.79% year-over-year to $125.1 million; the trailing twelve-month figure through Mar 2026 stood at $383.4 million (up 98.4% YoY), and the FY2025 full-year result was $315.5 million, up 88.71% from the prior year.
• Operating Expenses for Q1 2026 stood at $125.1 million, up from $94.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $125.1 million in Q1 2026 and bottomed at $15.1 million in Q2 2022.
• The 5-year median for Operating Expenses is $33.6 million (2022), against an average of $47.1 million.
• The widest annual swing landed in 2022, when Operating Expenses soared 260.92%; it then declined 19.51% in 2023.
• A 5-year view of Operating Expenses shows it stood at $33.6 million in 2022, then retreated by 19.51% to $27.0 million in 2023, then jumped by 80.98% to $48.9 million in 2024, then jumped by 92.6% to $94.2 million in 2025, then surged by 32.83% to $125.1 million in 2026.
• The last three Operating Expenses figures came in at $125.1 million (Q1 2026), $94.2 million (Q4 2025), and $83.9 million (Q3 2025), per Business Quant data.

Peer Comparison